Alumis Inc. shares dropped 56.76% after its Phase 2b trial for a lupus drug failed to meet key goals, though some patient groups showed promise. Enovis Corporation shares fell 16.51% following its announcement to acquire eCential Robotics for €155 million, with the deal expected to close by end of 2026. Leveraged ETFs also declined sharply amid the market downturn. These events highlight risks in biotech trials and strategic moves in medical tech sectors.
SPAC stocks like Rising Dragon Acquisition surged nearly 47% amid volatility, while biotech firm bioAffinity Technologies jumped 44% after a reverse stock split. Renewable energy company Fervo Energy gained 28% following a major geothermal power deal...
Enovis has lowered its price target to $27 from $30 following its binding offer to acquire eCential Robotics for €155 million. This acquisition aims to strengthen Enovis's position in surgical robotics and enhance its ASTRA technology ecosystem. Desp...
Citigroup reaffirmed its Buy rating on NIO but lowered the price target from $8.20 to $7.10 due to NIO's second-quarter deliveries and revenue missing company guidance and a third-quarter outlook below Wall Street estimates. Despite a 49.4% year-over...
Yum! Brands recently sold its Pizza Hut division and CEO Christopher Lee Turner sold shares amid legal scrutiny. The company is under investigation by Pomerantz LLP for possible securities fraud following a food safety crisis linked to a cyclosporias...
Dell Technologies reported quarterly revenue of $46.97 billion and earnings per share of $7.04, both surpassing analyst expectations. The company's growth is fueled by strong demand in its AI server business, supported by a substantial $51 billion or...
